Risk Without Reward: Differing Patterns of Chemotherapy Use Do Not Improve Outcomes in Stage II Early-Onset Colon Cancer
2024 · JCO Oncology Practice · 2 citations
https://doi.org/10.1200/op.24.00159
T
Tyler J. Friedrich
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
33
Papers
53
Citations
3
h-index
1
i10-index
Tyler J. Friedrich is an academic researcher from University of Colorado Health. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Colorectal Cancer Surgical Treatments & Cancer Immunotherapy and Biomarkers. The author has an h-index of 3, co-authored 29 publications.
ORCID: 0000-0002-2334-8144Papers by this author
worksSupplementary Figure S2 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024 · 0 citations
https://doi.org/10.1158/1078-0432.26926014
Supplementary Table S1 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024 · 0 citations
https://doi.org/10.1158/1078-0432.26925984.v1
Data from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024 · 0 citations
https://doi.org/10.1158/1078-0432.c.7429368
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat